News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,657 Results
Type
Article (42167)
Company Profile (436)
Press Release (669054)
Section
Business (208674)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83542)
Employer Resources (173)
FDA (16402)
Job Trends (15083)
News (352653)
Policy (33043)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2635)
Accelerated approval (3)
Adcomms (24)
Allergies (82)
Alliances (50888)
ALS (86)
Alzheimer's disease (1395)
Antibody-drug conjugate (ADC) (122)
Approvals (16390)
Artificial intelligence (242)
Autoimmune disease (16)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (330)
Bladder cancer (61)
Brain cancer (24)
Breast cancer (252)
Cancer (2020)
Cardiovascular disease (165)
Career advice (1686)
Career pathing (29)
CAR-T (146)
Cell therapy (416)
Cervical cancer (17)
Clinical research (67460)
Collaboration (803)
Compensation (452)
Complete response letters (24)
COVID-19 (2640)
CRISPR (39)
C-suite (214)
Cystic fibrosis (103)
Data (1948)
Decentralized trials (2)
Denatured (26)
Depression (44)
Diabetes (252)
Diagnostics (6389)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (116)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (90)
Earnings (87378)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115120)
Executive appointments (643)
FDA (17517)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (717)
Gene editing (102)
Generative AI (19)
Gene therapy (298)
GLP-1 (717)
Government (4465)
Grass and pollen (4)
Guidances (48)
Healthcare (19134)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (113)
Indications (27)
Infectious disease (2771)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (47)
Intellectual property (84)
Interviews (311)
IPO (16766)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (477)
Leadership (16)
Legal (7976)
Liver cancer (71)
Lung cancer (294)
Lymphoma (131)
Machine learning (2)
Management (58)
Manufacturing (274)
MASH (63)
Medical device (13465)
Medtech (13470)
Mergers & acquisitions (19696)
Metabolic disorders (663)
Multiple sclerosis (70)
NASH (19)
Neurodegenerative disease (88)
Neuropsychiatric disorders (30)
Neuroscience (1892)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2421)
Now hiring (37)
Obesity (361)
Opinion (220)
Ovarian cancer (73)
Pain (79)
Pancreatic cancer (77)
Parkinson's disease (136)
Partnered (20)
Patents (203)
Patient recruitment (94)
Peanut (47)
People (58435)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21192)
Phase II (29771)
Phase III (22015)
Pipeline (998)
Podcasts (73)
Policy (116)
Postmarket research (2601)
Preclinical (9041)
Press Release (67)
Prostate cancer (95)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (376)
Real estate (6008)
Recruiting (66)
Regulatory (22586)
Reports (46)
Research institute (2412)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (3)
RSV (37)
Schizophrenia (70)
Series A (129)
Series B (83)
Service/supplier (11)
Sickle cell disease (54)
Southern California (2104)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (44)
United States (21457)
Vaccines (672)
Venture capitalists (38)
Webinars (13)
Weight loss (244)
Women's health (35)
Worklife (16)
Date
Today (93)
Last 7 days (620)
Last 30 days (2556)
Last 365 days (34588)
2025 (7939)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (735)
Alabama (54)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (39106)
Australia (6508)
California (5584)
Canada (1868)
China (479)
Colorado (251)
Connecticut (268)
Delaware (126)
Europe (85360)
Florida (813)
Georgia (190)
Idaho (57)
Illinois (507)
India (23)
Indiana (293)
Iowa (10)
Japan (142)
Kansas (103)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (845)
Massachusetts (4266)
Michigan (210)
Minnesota (372)
Mississippi (2)
Missouri (76)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1585)
New Mexico (30)
New York (1586)
North Carolina (977)
North Dakota (7)
Northern California (2421)
Ohio (193)
Oklahoma (14)
Oregon (37)
Pennsylvania (1259)
Puerto Rico (9)
Rhode Island (27)
South America (1108)
South Carolina (18)
South Dakota (1)
Southern California (2104)
Tennessee (92)
Texas (831)
Utah (166)
Virginia (131)
Washington D.C. (59)
Washington State (526)
West Virginia (3)
Wisconsin (50)
711,657 Results for "agex therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
March 22, 2024
·
15 min read
Deals
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, today announced the closing of its previously announced merger with a wholly-owned subsidiary of AgeX Therapeutics, Inc.
March 26, 2024
·
12 min read
Business
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
November 14, 2023
·
13 min read
Deals
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction.
August 30, 2023
·
16 min read
Business
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
August 14, 2023
·
10 min read
Biotech Bay
AgeX Therapeutics Announces Appeal of NYSE American Determination
AgeX Therapeutics, Inc. announced that on May 17, 2023 it received a notice from the staff of the NYSE American indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003, and of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023.
May 23, 2023
·
3 min read
Biotech Bay
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
AgeX Therapeutics, Inc. reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.
July 24, 2023
·
8 min read
Business
AgeX Therapeutics Reports First Quarter 2023 Financial Results
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.
May 12, 2023
·
9 min read
Biotech Bay
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.
July 21, 2023
·
9 min read
Business
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.
March 31, 2023
·
10 min read
1 of 71,166
Next